Wire · regulatory
Kenya reviews Mounjaro market entry
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
Kenya's Pharmacy and Poisons Board has started reviewing Aspen Pharmacare's application to register Mounjaro, a diabetes medication containing tirzepatide, signaling a potential new treatment option pending regulatory approval. This review is a preliminary step in the registration process and forms part of Aspen's strategy to expand Mounjaro's reach in sub-Saharan Africa.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Your access to the Kenyan diabetes market might open soon as Mounjaro enters regulatory review, creating a door for suppliers of diabetes care solutions or complementary services. Watch this approval closely to position against rising competition from generics and other GLP-1 treatments.
◆ Coverage
1 source · 10 Sep 2026
◆ Related on Wire
◆ Topics